NORTHWEST BIO SHARED RESOURCE (NWBioSR) Northwest Bio Shared Resource (NWBioSR) provides patient consenting, human research biospecimen procurement, and annotation services. Patients are consented for (1) research use of biospecimens and electronic medical records-derived data and (2) enrollment in a registry of patients who consent to future contact for potential enrollment in clinical studies. All biospecimen and data handling is done under Institutional Review Board (IRB)-approved mechanisms. NWBioSR is organized under a Governance Committee with Consortium-wide representation and support. State-of-the-art information systems support operations, allowing broad Consortium access to: ? Registration of studies, associated IRB, and consent information ? Prospective identification of clinical samples, from which research biospecimens likely may be obtained, based on characteristics determined electronically prior to actual arrival of the clinical specimen in the hospital laboratory: 1. at the patient level, such as demographic information 2. at the visit level, such as tumor type and stage information 3. at the biospecimen level, such as aliquot stabilization time ? Procurement of research-only biospecimens, including blood draws obtained specifically for research and research-only biopsies ? Retrospective identification of clinical samples that pre-exist in the hospital laboratories and which may be used/subdivided for research (e.g., archival pathology blocks and slides as well as remnant blood ?leftover? in the laboratory medicine department from earlier clinical draws); ? Detailed annotation information including extensive extraction of medical records data as needed ? Generation of tissue microarrays as well as digital pathology image annotation and analysis of whole slide images ? Dissemination of biospecimen and annotation information through informatics efforts NWBioSR is a heavily-utilized facility, supporting a large number of clinical trials, translational research studies, Consortium biorepository collections, and external projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015704-45
Application #
9853653
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
45
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Puronen, Camille E; Cassaday, Ryan D; Stevenson, Philip A et al. (2018) Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. Biol Blood Marrow Transplant 24:2211-2215
Gavvovidis, Ioannis; Leisegang, Matthias; Willimsky, Gerald et al. (2018) Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus. Clin Cancer Res 24:3644-3655
Paulson, K G; Voillet, V; McAfee, M S et al. (2018) Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat Commun 9:3868
Verboon, Jeffrey M; Decker, Jacob R; Nakamura, Mitsutoshi et al. (2018) Correction: Wash exhibits context-dependent phenotypes and, along with the WASH regulatory complex, regulates Drosophila oogenesis (doi:10.1242/211573). J Cell Sci 131:
Witzky, Anne; Hummels, Katherine R; Tollerson 2nd, Rodney et al. (2018) EF-P Posttranslational Modification Has Variable Impact on Polyproline Translation in Bacillus subtilis. MBio 9:
Rosenthal, Elisabeth A; Shirts, Brian H; Amendola, Laura M et al. (2018) Rare loss of function variants in candidate genes and risk of colorectal cancer. Hum Genet 137:795-806
Sillah, Arthur; Watson, Nathaniel F; Schwartz, Stephen M et al. (2018) Sleep apnea and subsequent cancer incidence. Cancer Causes Control 29:987-994
Hay, Kevin A; Turtle, Cameron J (2018) CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era. Immunotherapy 10:251-254
Davis, Ryan J; Gönen, Mehmet; Margineantu, Daciana H et al. (2018) Pan-cancer transcriptional signatures predictive of oncogenic mutations reveal that Fbw7 regulates cancer cell oxidative metabolism. Proc Natl Acad Sci U S A 115:5462-5467
Sullivan, Kevin M; Kenerson, Heidi L; Pillarisetty, Venu G et al. (2018) Precision oncology in liver cancer. Ann Transl Med 6:285

Showing the most recent 10 out of 1267 publications